# Latigo Biotherapeutics, Inc. (LTGO)

> Source: Nexqual · https://nexqual.com/LTGO · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Latigo Biotherapeutics, Inc. (LTGO), nexqual.com/LTGO" · informational, not investment advice.

**Price:** USD 15.54 (-1.83% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 15.83 · day 15.44–16.74 · 52w 13.5–25.93 · market cap $1.03B · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 52.25 (range 36–73).
- Total return with dividends: 1Y -13.3% vs S&P 500 +14.8%; 5Y -14.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.67, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: LTGO paid no cash dividend in the last five years.
- Short interest: 785,880 shares (as of 2026-10-15), 1.9 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
Earnings yield -9.10% · Net cash $20.0M · EV $1.03B

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 52.25 (low 36, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-01 | Leerink Partners | Initiated | Outperform | $36 |
| 2026-09-01 | Jefferies | Initiated | Buy | $50 |
| 2026-09-01 | Guggenheim | Initiated | Buy | $50 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-08-07) | 5Y (from 2026-08-03) |
|---|---|---|
| Total return | -13.3% | -14.8% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 75.4% | 77.5% |
| Max drawdown | -44.0% (Aug 2026→Oct 2026) | -42.2% (Aug 2026→Oct 2026) |

## Dividends
LTGO paid no cash dividend in the last five years.

## Short interest
785,880 shares sold short, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 449,962 shares (+74.7%). Days to cover: 1.9 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/LTGO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.67 | $0.00 | −$0.67 | $0 | 2 |
| Next quarter (ends 2026-12-31) | $-0.85 | $0.00 | −$0.85 | $0 | 2 |
| Current fiscal year (ends 2026-12-31) | $-3.01 | $0.00 | −$3.01 | $0 | 3 |
| Next fiscal year (ends 2027-12-31) | $-2.32 | $0.00 | −$2.32 | $0 | 4 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$27.59 | −$0.66 | Miss −4080.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).